86.66
+1.26(+1.48%)
Currency In USD
| Previous Close | 85.4 |
| Open | 86.44 |
| Day High | 87.63 |
| Day Low | 82.72 |
| 52-Week High | 90.33 |
| 52-Week Low | 33.01 |
| Volume | 415,063 |
| Average Volume | 389,143.6 |
| Market Cap | 1.62B |
| PE | -9.45 |
| EPS | -9.17 |
| Moving Average 50 Days | 75.71 |
| Moving Average 200 Days | 61.21 |
| Change | 1.26 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $207.82 as of February 14, 2025 at a share price of $86.66. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $452.77 as of February 14, 2025 at a share price of $86.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 04, 2025 10:00 PM GMT
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte
Praxis Precision Medicines to Present at Two February Investor Conferences
GlobeNewswire Inc.
Feb 03, 2025 10:00 PM GMT
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
GlobeNewswire Inc.
Jan 13, 2025 2:00 AM GMT
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 inte